Wall Street brokerages expect that Agilent Technologies Inc (NYSE:A) will post sales of $1.17 billion for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Agilent Technologies’ earnings, with the highest sales estimate coming in at $1.19 billion and the lowest estimate coming in at $1.16 billion. Agilent Technologies reported sales of $1.11 billion during the same quarter last year, which indicates a positive year over year growth rate of 5.4%. The business is expected to issue its next quarterly earnings results after the market closes on Monday, November 20th.

According to Zacks, analysts expect that Agilent Technologies will report full year sales of $1.17 billion for the current year, with estimates ranging from $4.44 billion to $4.47 billion. For the next fiscal year, analysts anticipate that the business will report sales of $4.72 billion per share, with estimates ranging from $4.68 billion to $4.76 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Agilent Technologies.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 15.71% and a return on equity of 15.63%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm earned $0.49 earnings per share. Agilent Technologies’s revenue was up 6.7% on a year-over-year basis.

A has been the topic of a number of recent research reports. BidaskClub cut shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 12th. Janney Montgomery Scott lifted their target price on shares of Agilent Technologies from $65.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, August 16th. Robert W. Baird reaffirmed a “buy” rating and issued a $70.00 target price on shares of Agilent Technologies in a report on Friday, October 20th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $70.00 target price on shares of Agilent Technologies in a report on Wednesday, August 16th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $68.00 target price on shares of Agilent Technologies in a report on Tuesday, September 26th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Agilent Technologies currently has an average rating of “Buy” and a consensus target price of $65.65.

Shares of Agilent Technologies (A) traded up 0.15% during trading on Thursday, hitting $67.49. 134,715 shares of the company’s stock were exchanged. The stock has a market cap of $21.72 billion, a P/E ratio of 34.81 and a beta of 1.30. The firm has a 50-day moving average price of $65.92 and a 200-day moving average price of $60.76. Agilent Technologies has a one year low of $42.92 and a one year high of $68.52.

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 25th. Shareholders of record on Tuesday, October 3rd were given a dividend of $0.132 per share. The ex-dividend date was Monday, October 2nd. This represents a $0.53 annualized dividend and a dividend yield of 0.78%. Agilent Technologies’s payout ratio is currently 27.32%.

In related news, insider Dominique Grau sold 13,007 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $62.00, for a total value of $806,434.00. Following the sale, the insider now directly owns 60,098 shares in the company, valued at approximately $3,726,076. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Doak sold 12,421 shares of the business’s stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $61.57, for a total transaction of $764,760.97. The disclosure for this sale can be found here. Insiders have sold a total of 165,720 shares of company stock worth $10,488,739 over the last 90 days.

Several institutional investors have recently added to or reduced their stakes in A. Neuberger Berman Group LLC boosted its position in shares of Agilent Technologies by 0.9% in the 1st quarter. Neuberger Berman Group LLC now owns 9,840 shares of the medical research company’s stock worth $520,000 after buying an additional 91 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Agilent Technologies by 1.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,156,150 shares of the medical research company’s stock worth $61,128,000 after buying an additional 17,169 shares in the last quarter. Granahan Investment Management Inc. MA purchased a new stake in shares of Agilent Technologies in the 1st quarter worth about $348,000. Highbridge Capital Management LLC boosted its position in shares of Agilent Technologies by 3,379.7% in the 1st quarter. Highbridge Capital Management LLC now owns 22,958 shares of the medical research company’s stock worth $1,214,000 after buying an additional 23,658 shares in the last quarter. Finally, BlueCrest Capital Management Ltd purchased a new stake in shares of Agilent Technologies in the 1st quarter worth about $253,000.

TRADEMARK VIOLATION WARNING: “Agilent Technologies Inc (A) Expected to Announce Quarterly Sales of $1.17 Billion” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/26/agilent-technologies-inc-a-expected-to-announce-quarterly-sales-of-1-17-billion.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Get a free copy of the Zacks research report on Agilent Technologies (A)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.